BioAdaptives Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BDPT research report →
Price Chart
About the company
BioAdaptives, Inc. is a research and development company that develops and markets nutraceutical and dietary supplement products for humans and animals. Its products are derived from natural plant, fungi, and algal-based sources and include supplements for cognitive enhancement, weight management, and regenerative wellness.
- CEO
- James Keener
- IPO
- 2016
- Employees
- 1
- HQ
- Las Vegas, NV, US
Get TickerSpark's AI analysis on BDPT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $18.01K
- P/E
- -0.01
- PEG
- 0.00
- P/S
- 0.70
- P/B
- -0.01
- EV/EBITDA
- -0.40
- Div Yield
- 0.00%
- Gross Margin
- 74.48%
- Op Margin
- -3551.11%
- Net Margin
- -4553.73%
- ROE
- 62.10%
- ROIC
- 73.00%
Latest fiscal year · YoY change
- Revenue
- $18.28K+44.3%
- Gross Profit
- $12.50K+210.1%
- Op Income
- $-1,042,173
- Net Income
- $-1,557,898-73.3%
- EPS
- $-0.15-36.4%
- OCF Growth
- -106.8%
- FCF Growth
- -114.0%
- 52W High
- $0.06
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.01
- Beta
- 1.11
- RSI (14)
- 44
- Avg Volume
- 27.05M
No earnings-call transcripts are available for BDPT yet.
- Free Float
- 99.8%
- Shares Outstanding
- 196.93M
- Float Shares
- 11.99M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | FRISSORA MARK P | other | 15,625 |
| Sep 1, 26 | FRISSORA MARK P | other | 35,715 |
| Aug 1, 26 | FRISSORA MARK P | other | 15,152 |
| Jul 1, 26 | FRISSORA MARK P | other | 12,500 |
| Jun 1, 26 | FRISSORA MARK P | other | 4,717 |
| May 1, 26 | FRISSORA MARK P | other | 4,808 |
| Apr 1, 26 | FRISSORA MARK P | other | 4,386 |
| Mar 1, 26 | FRISSORA MARK P | other | 2,578 |
| Feb 1, 26 | FRISSORA MARK P | other | 2,565 |
| Jan 1, 26 | FRISSORA MARK P | other | 2,286 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BDPT coverage
Recent articles, reports, and earnings notes.
No research on BDPT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BDPT report →BioAdaptives Highlights Michael Bisping's MyndMed(TM) Routine in UFC 331 Pre-Show Instagram Video
accessnewswire.com · Sep 23
BioAdaptives Confirms First Commercial Orders of XcellaraHeart(TM) and Outlines Capital Restructuring Progress
accessnewswire.com · Sep 3
UFC Hall of Famer Michael Bisping Joins BioAdaptives to Champion MyndSystem(TM)
accessnewswire.com · Aug 31
BioAdaptives, Inc. Announces CEO's Share Cancellation and Provides Capital Restructure Update
accessnewswire.com · Aug 13
BioAdaptives Inc. Introduces XcellaraHeart(TM): the World's First Stem Cell Mobilizer with a Targeted Cardiac Homing Signal
accessnewswire.com · Aug 12
BioAdaptives Inc. Opens Commercial Ordering Window for XcellaraHeart(TM) Cellular Wellness Formula
accessnewswire.com · Aug 3
BioAdaptives Inc. Eliminates Major Market Overhang by Retiring the Debt of the Largest Convertible Commercial Investor
accessnewswire.com · Jul 30
BioAdaptives Inc. Reports Scaling of E-Commerce Footprint and Consumer Reach for MyndSystem(TM) Nootropic Platform
accessnewswire.com · Jul 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.